Fuad El-Hibri on Businessweek
Fuad El-Hibri has been Chairman and Chief Executive Officer of Emergent Biodefense Operations Lansing Inc., a subsidiary of Emergent Biosolutions Inc. since June 2004. Mr. El-Hibri founded Emergent Biosolutions Inc. in 2004 and has been its Chairman and Chief Executive Officer since June 2004. He served as President of Emergent BioSolutions, Inc. from March 2006 [...]
August 17, 2009
Tags: Business, Chairman, Chief executive officer, Emergent BioSolutions, Employment, Management, President, Recruitment and Staffing Posted in: Businessweek, El-Hibri, Emergent BioSolutions, Social Network, United States, fuad el-hibri 
No Comments
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
August 13, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine Posted in: Anthrax vaccines, Emergent BioSolutions, Infectious disease, U.S. Food and Drug Administration No Comments
EMERGENT BIOSOLUTIONS ANTICIPATES 2ND QUARTER BIOTHRAX REVENUES OF APPROXIMATELY $20 MILLION BASED ON ACCELERATED DELIVERY TO DEPARTMENT OF DEFENSE
ROCKVILLE, MD, June 27, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Department of Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax® (Anthrax Vaccine Adsorbed) during the quarter ending June 30, 2007 or shortly thereafter. The company anticipates [...]
July 15, 2009
Tags: Anthrax vaccines, Emergent BioSolutions, Infectious disease, Private Securities Litigation Reform Act, U.S. Department of Defense, U.S. Food and Drug Administration, U.S. government, United States Posted in: Uncategorized No Comments
EMERGENT BIOSOLUTIONS ANNOUNCES RESULTS FROM ANNUAL MEETING OF STOCKHOLDERS
ROCKVILLE, MD, June 14, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today the results of the company’s 2007 annual meeting of stockholders, which took place today at the Hyatt Regency Bethesda at 10:00 am Eastern.
There were present, in person or represented by proxy, the holders of more than a majority of the shares [...]
July 15, 2009
Tags: Anthrax, Anthrax vaccines, Business, Company, Emergent BioSolutions, Health, Infectious disease, U.S. Food and Drug Administration Posted in: Uncategorized No Comments
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
July 15, 2009
Tags: Anthrax vaccines, Board of directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, United States, US Food and Drug Administration Posted in: Uncategorized No Comments
Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense.
Company Preparing Response to DoD Request for Proposal for Delivery of Up to 14 Million Additional Doses of BioThrax
ROCKVILLE, Md. — Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Department of Defense (DoD), it anticipates completing delivery of 900,000 doses of BioThrax([R]) [...]
July 15, 2009
Tags: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Federal government of the United States, Immunization, United States, United States Department of Defense, US government Posted in: Uncategorized No Comments
Emergent Biosolutions And Ninebio Sdn. Bhd. Announce Joint Venture In Malaysia
Newly formed company to focus on creating critical R&D and manufacturing infrastructure and supplying biodefense countermeasures within Asia and other territories.
Emergent BioSolutions (NYSE: EBS) and Ninebio Sdn. Bhd. (“9Bio”) today announced the formation of a joint venture in Malaysia that will focus on creating critical biologics infrastructure and supplying biodefense countermeasures, including BioThrax® (Anthrax Vaccine [...]
July 11, 2009
Tags: Chief executive officer, Emergent BioSolutions, MALAYSIA, Private Securities Litigation Reform Act, Research and development, SEC, U.S. Food and Drug Administration, United States Posted in: Uncategorized No Comments